Full Press Release Details
RESEARCH TRIANGLE PARK, N.C., March 03, 2026 (GLOBE NEWSWIRE) --Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the following investor conferences.
Leerink Global Healthcare Conference
Date: Tuesday, March 10, 2026
Time: 3:00 p.m. ET
Location: Miami, FL
Citizens Life Sciences Conference
Date: Wednesday, March 11, 2026
Time: 2:50 p.m. ET
Location: Miami, FL
RBC Capital Markets Global Ophthalmology Conference
Date: Wednesday, March 25, 2026
Time: 11:45 a.m. ET
Location: Virtual
Links to the conference webcasts may be accessed on Opus Genetics’ website under the Investors section:Events.
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, an approved small-molecule therapy for pharmacologically induced mydriasis, with additional potential indications in presbyopia and low-light visual disturbances following keratorefractive surgery. The Company is based in Research Triangle Park, NC. For more information, visitwww.opusgtx.com.
InvestorsJenny KobinRemy BernardaIR Advisory Solutionsir@opusgtx.com
MediaKimberly HaKKH Advisors917-291-5744kimberly.ha@kkhadvisors.com
Source: Opus Genetics, Inc.